De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim.

Slides:

Advertisements

Similar presentations

Dr Nauman Butt – Royal Liverpool University Hospital CML Patient Seminar - 14 th November 2015 What is CML? How do we treat it? Get up to speed…

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 14, Issue 4, Pages (April 2013)

Volume 379, Issue 9824, Pages (April 2012)

Volume 367, Issue 9517, Pages (April 2006)

Volume 357, Issue 9257, Pages (March 2001)

Volume 376, Issue 9747, Pages (October 2010)

Volume 16, Issue 9, Pages (September 2015)

Effect of a bereavement support group on female adolescents' psychological health: a randomised controlled trial in South Africa Prof Tonya Renee Thurman,

Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised,

Volume 376, Issue 9734, Pages (July 2010)

Thank God for Richard Dawkins?

Volume 372, Issue 9633, Pages (July 2008)

The electronic future of scientific articles

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 389, Issue 10076, Pages (April 2017)

Volume 16, Issue 13, Pages (October 2015)

Volume 371, Issue 9611, Pages (February 2008)

Volume 376, Issue 9734, Pages (July 2010)

Volume 9, Issue 5, Pages (May 2008)

Volume 366, Issue 9482, Pages (July 2005)

Volume 14, Issue 3, Pages (March 2013)

Volume 15, Issue 8, Pages (July 2014)

Volume 390, Issue 10092, Pages (July 2017)

Volume 372, Issue 9633, Pages (July 2008)

Volume 366, Issue 9486, Pages (August 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 376, Issue 9757, Pages (December 2010)

Volume 366, Issue 9482, Pages (July 2005)

Volume 15, Issue 4, Pages (April 2014)

Volume 389, Issue 10071, Pages (February 2017)

Volume 373, Issue 9663, Pages (February 2009)

Volume 372, Issue 9642, Pages (September 2008)

Volume 390, Issue 10092, Pages (July 2017)

Volume 2, Issue 6, Pages (June 2015)

Misoprostol for small bowel ulcers in patients with obscure bleeding taking aspirin and non-steroidal anti-inflammatory drugs (MASTERS): a randomised,

The effect of explosive remnants of war on global public health: a systematic mixed- studies review using narrative synthesis Alexandra Frost, MSc, Prof.

Volume 15, Issue 6, Pages (May 2014)

Volume 375, Issue 9732, Pages (June 2010)

Volume 4, Issue 6, Pages (June 2017)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised,

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Volume 382, Issue 9888, Pages (July 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 15, Issue 8, Pages (July 2014)

The effect of a conditional cash transfer on HIV incidence in young women in rural South Africa (HPTN 068): a phase 3, randomised controlled trial Dr.

Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): a double-blind, randomised controlled trial

Volume 378, Issue 9786, Pages (July 2011)

Volume 381, Issue 9880, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 5, Issue 4, Pages (April 2018)

Thank God for Richard Dawkins?

Volume 375, Issue 9714, Pages (February 2010)

Volume 376, Issue 9757, Pages (December 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 13, Issue 7, Pages (July 2014)

Volume 372, Issue 9632, Pages (July 2008)

Effect of a behaviour change intervention on the quality of peri-urban sanitation in Lusaka, Zambia: a randomised controlled trial James B Tidwell, PhD,

Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label.

Volume 20, Issue 5, Pages (May 2019)

Volume 14, Issue 7, Pages (June 2013)

The escalating global burden of serious health-related suffering: projections to 2060 by world regions, age groups, and health conditions Katherine E.

Volume 371, Issue 9611, Pages (February 2008)

Volume 6, Issue 7, Pages (July 2019)

Presentation transcript:

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial Prof Richard E Clark, MD, Fotios Polydoros, MSc, Prof Jane F Apperley, MD, Dragana Milojkovic, PhD, Christopher Pocock, PhD, Graeme Smith, MD, Jenny L Byrne, PhD, Hugues de Lavallade, MD, Prof Stephen G O'Brien, PhD, Tony Coffey, Prof Letizia Foroni, PhD, Prof Mhairi Copland, PhD The Lancet Haematology Volume 4, Issue 7, Pages e310-e316 (July 2017) DOI: 10.1016/S2352-3026(17)30066-2 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile MMR=major molecular response (BCR-ABL1:ABL1 ratio consistently <0·1%). MR4=deep molecular response (BCR-ABL1:ABL1 ratio <0·01%). TKI=tyrosine kinase inhibitor. The Lancet Haematology 2017 4, e310-e316DOI: (10.1016/S2352-3026(17)30066-2) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 2 Relapse-free survival (A) and time to MMR recovery (B) MMR=major molecular response (BCR-ABL1:ABL1 ratio consistently <0·1%). MR4=deep molecular response (BCR-ABL1:ABL1 ratio <0·01%). HR=hazard ratio. The Lancet Haematology 2017 4, e310-e316DOI: (10.1016/S2352-3026(17)30066-2) Copyright © 2017 Elsevier Ltd Terms and Conditions